U.S. FDA Extends Review of sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple Sclerosis
Go back to U.S. FDA Extends Review of sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple Sclerosis| (NASDAQ: GMAB) | Delayed: 25.08 -0.16 (0.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.24 | 52 Week High | $ | |||
| Open | $25.07 | 52 Week Low | $ | |||
| Day High | $25.26 | P/E | N/A | |||
| Day Low | $24.93 | EPS | $ | |||
| Volume | 1,113,722 | |||||
